MedTrace Logo

TYRO Champion Dads Project Study

NCT05256992 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 748

Last updated 2025-11-21

Study results available
· View outcomes & findings →

Summary

This impact evaluation aims to determine if the addition of 10 hours of domestic violence prevention programming is effective at improving outcomes among those program participants who are randomly assigned to the treatment group. Both study groups will receive standard TYRO Champion Dads services (the TYRO Dads and TYRO Core Communication evidence-based curricula, plus support services), but only the treatment group will be offered the additional Ray of Hope curriculum hours focused on mitigating risk factors related to domestic violence.

Conditions

  • Fathers

Interventions

OTHER

Standard Servies + Ray of Hope Curriculum

Standard services delivered as primary services to participants in both study groups under a shared condition are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula. Optional services available to both study groups by selecting 1-3 hours of coursework from menu of courses that address a variety of needs.

OTHER

Standard Services

Standard services delivered as primary services to participants in both study groups under a shared condition are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula.

Sponsors & Collaborators

  • Anthem Strong Families

    collaborator UNKNOWN

  • Midwest Evaluation & Research

    lead OTHER

Principal Investigators

  • Matt D Shepherd, PhD · Midwest Evaluation & Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2025-05-01
Completion
2025-08-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05256992 on ClinicalTrials.gov